THC.CSE THCBF – OTC TFHD.F
Vancouver, BC – (March 1, 2023) THC BioMed Intl Ltd. (“THC BioMed” or the “Company”) is pleased to announce that its patented Clone Shipper containers are now available for purchase in Asia. Clone Shipper containers are available for purchase from THC BioMed Thailand. Clone Shipper is a profit-making subsidiary of THC BioMed Intl Ltd.
We are pleased to begin sales and export of our American-manufactured Clone Shipper products to Asia. THC2Go dispensaries will also carry Clone Shipper containers for sale.
The innovative Clone Shipper container’s patented design enables plants, especially clones or young plants, to be shipped safely and all the while nurturing the plant in the growing process. This container is built to last for multiple shipments. The latest innovations include a new opaque lid and an LED light that lasts for 100 hours or longer.
THC BioMed is incredibly pleased to have entered the Asian medical cannabis market while it is still in its infancy. THC BioMed anticipates massive growth in the Asian medical cannabis sector and is well-positioned to embrace what has the potential to be the largest medical cannabis market in the world.
THC BioMed is one of Canada’s oldest active licensed cannabis companies. It was first licensed to deal with cannabis in 2013 under a Health Canada Section 56 exemption under the Controlled Drugs and Substances Act and has been a Licensed Producer under the current regime since 2016. It aims to be a leader in the beverage and edible space.
THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services in the medical and recreational cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this rapidly growing industry.
President and CEO:
THC BioMed Intl Ltd.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements using words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements in this release include that (a) THC2Go dispensaries will carry Clone Shipper containers for sale, (b) there will be massive growth in the Asian medical cannabis sector, (c) the Asian market could become the largest medical cannabis market in the world and (d) THC BioMed is well-positioned to embrace growth in the Asian market and the cannabis industry. Forward-looking statements in this release are made as of the date of this press release and include that THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.